全文获取类型
收费全文 | 986篇 |
免费 | 51篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 42篇 |
妇产科学 | 4篇 |
基础医学 | 74篇 |
口腔科学 | 9篇 |
临床医学 | 94篇 |
内科学 | 115篇 |
皮肤病学 | 196篇 |
神经病学 | 34篇 |
特种医学 | 95篇 |
外科学 | 133篇 |
综合类 | 31篇 |
一般理论 | 10篇 |
预防医学 | 32篇 |
眼科学 | 96篇 |
药学 | 57篇 |
肿瘤学 | 19篇 |
出版年
2023年 | 5篇 |
2022年 | 11篇 |
2021年 | 31篇 |
2020年 | 14篇 |
2019年 | 18篇 |
2018年 | 23篇 |
2017年 | 28篇 |
2016年 | 24篇 |
2015年 | 20篇 |
2014年 | 31篇 |
2013年 | 36篇 |
2012年 | 47篇 |
2011年 | 46篇 |
2010年 | 35篇 |
2009年 | 21篇 |
2008年 | 54篇 |
2007年 | 65篇 |
2006年 | 43篇 |
2005年 | 59篇 |
2004年 | 53篇 |
2003年 | 52篇 |
2002年 | 51篇 |
2001年 | 37篇 |
2000年 | 11篇 |
1999年 | 11篇 |
1998年 | 12篇 |
1997年 | 7篇 |
1996年 | 13篇 |
1995年 | 16篇 |
1994年 | 9篇 |
1993年 | 13篇 |
1992年 | 12篇 |
1991年 | 8篇 |
1990年 | 9篇 |
1989年 | 9篇 |
1988年 | 9篇 |
1987年 | 8篇 |
1986年 | 6篇 |
1985年 | 9篇 |
1984年 | 5篇 |
1983年 | 6篇 |
1982年 | 5篇 |
1980年 | 4篇 |
1979年 | 7篇 |
1978年 | 4篇 |
1975年 | 6篇 |
1973年 | 6篇 |
1971年 | 5篇 |
1966年 | 3篇 |
1961年 | 3篇 |
排序方式: 共有1049条查询结果,搜索用时 15 毫秒
1.
2.
3.
Three hundred and seventeen recent clinical isolates were tested for in vitro susceptibility to the three cephalosporins available in India--cephalexin, cefazolin and cefotaxime by the Kirby--Bauer disc diffusion method. Cefazolin was the most effective cephalosporin against Gram positive cocci (71.8% sensitive) followed by cefotaxime (62.7%) and cephalexin (52.7%). Cefotaxime was very effective against commonly isolated Gram negative bacilli with only 10 (8.8%) isolates being resistant to it while 44 (39%) and 65 (57.5%) were resistant to cefazolin and cephalexin, respectively. All isolates of Pseudomonas aeruginosa were resistant to cephalexin and cefazolin and only 29 (32.6%) were sensitive to cefotaxime. 相似文献
4.
5.
D. K. Bhargava M.D. Ph.D. B. Singh D.M. R. Dogra D.M. S. Dasarathy D.M. M. P. Sharma D.M. 《The American journal of gastroenterology》1992,87(2):182-186
A prospective randomized controlled study was designed to evaluate differences in efficacy and complication rate between the two most commonly used sclerosing agents, sodium tetradecyl sulfate (STD) and polidocanol. Of 52 patients with esophageal variceal bleeding, 26 were randomized to receive sclerotherapy with 1.5% STD and 26 to receive 1% polidocanol at weekly intervals. Eradication of varices was achieved in 88% patients each of the STD and polidocanol group. There was no significant difference between patients injected with STD and polidocanol with regard to re-bleeding (27% vs. 15%) and mortality (11.5% in both). The use of STD, in contrast to polidocanol, was associated with a higher incidence of complications in terms of severe retrosternal pain (27% vs. 4%), deep ulceration (53% vs. 23%), dysphagia (88% vs. 46%), and stricture formation (27% vs. 8%). It was concluded that these two agents were similar in efficacy. However, polidocanol was superior due to a lower incidence of complications. 相似文献
6.
Malathion induced changes in the serum proteins and hematological parameters of an Indian catfish Heteropneustes fossilis (Bloch) 总被引:2,自引:0,他引:2
7.
Perfluorochemicals as US contrast agents for tumor imaging and hepatosplenography: preliminary clinical results 总被引:3,自引:0,他引:3
Mattrey RF; Strich G; Shelton RE; Gosink BB; Leopold GR; Lee T; Forsythe J 《Radiology》1987,163(2):339-343
In animals, perfluorochemicals (PFCs) are effective ultrasound (US) contrast agents that produce hepatic, splenic, and tumor enhancement. The use of Fluosol-DA 20%, an emulsion of perfluorodecalin and perfluorotripropylamine, was studied in nine non-critically ill patients with cancer who had liver lesions. US studies without Fluosol were compared with studies obtained 24, 48, and 72 hours after Fluosol infusion. Vital signs and extensive laboratory analyses are performed before and after Fluosol infusion. Liver metastases from colonic, pancreatic, and gastric carcinoma exhibited rim or diffuse enhancement after a Fluosol dose of 1.6 g/kg or greater. Fluosol produced echogenic enhancement of the liver and spleen relative to kidney at a dose of 2.4 g/kg, allowing the detection of nonenhancing lesions. In addition, Fluosol at a dose of 1.6 g/kg or greater allowed detection of lesions not seen before contrast medium was administered in three of the seven patients studied. There was a mild increase in the level of serum glutamic oxaloacetic transaminase in two patients, one given 2.4 and the other 3.2 g/kg of Fluosol. Mild and transient allergic reactions without change in vital signs were experienced by two patients. 相似文献
8.
Classical and anaplastic seminoma: difference in survival 总被引:1,自引:0,他引:1
Classical and anaplastic seminoma are traditionally treated with radiation therapy and are said to have the same prognosis. A retrospective study was undertaken of 90 seminoma patients treated with radiation therapy between 1961 and 1985. The classical group consisted of 71 patients of whom 50 had stage I and 21 had stage II disease. The anaplastic group consisted of 19 patients of whom ten had stage I and nine had stage II disease. The median follow-up time was 64 months for the entire group. The 10-year relapse-free survival rate for the classical group was 94% and for the anaplastic group was 70% (P less than .05). For patients with classical stage I disease, the relapse-free actuarial survival rate was 98%; for patients with anaplastic stage I disease, it was 64% (P less than .02). For the classical stage II disease group, the relapse-free actuarial survival rate was 84% and for the anaplastic stage II disease group, 75% (P less than .70). Four patients in the classical group (6%) had relapses; of these, one patient had local recurrence of tumor, and three had distant metastases. In the anaplastic group, four patients (21%) had relapses; two patients had local recurrence of tumor, and two had distant metastases. Therefore the data suggest a difference in survival and relapse rates between classical and anaplastic seminoma. 相似文献
9.
Twenty patients with nodulocystic acne were randomly allocated to one of two treatment schedules: 1) Tetracycline 500 mg or 2) Tab. Gugulipid (equivalent to 25 mg guggulsterone). Both were taken twice daily for 3 months, and both produced a progressive reduction in the lesions in the majority of patients. With tetracycline, the percentage reduction in the inflammatory lesions was 65.2% as compared to 68% with gugulipid; on comparison, this difference was statistically insignificant (P>0.05). Follow-up at 3 months showed a relapse in 4 cases on tetracyline and 2 cases on gugulipid. An interesting observation was that the patients with oily faces responded remarkably better to gugulipid. 相似文献
10.